NCT00869726View on ClinicalTrials.gov

A Study for Patients With Secondary Progressive Multiple Sclerosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

596

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Secondary Progressive Multiple Sclerosis
Interventions
DRUG

dirucotide

500mg, intravenous, dosed once every six months for 18 months

DRUG

Placebo

intravenous, once every six months for 18 months

Trial Locations (10)

1015

Vecmilgravis Hospital, Riga

2100

Copenhagen University Hospital, Copenhagen

10617

West Tallinn Central Hospital, Tallinn

14186

Karolinska Universitetssjukhus, Stockholm

20101

Terveystalo Turku Kuvantaminen, Turku

40225

Heinrich Heine Universitaets, Düsseldorf

M5B 1W8

St. Michaels Hospital, Toronto

6131 BK

Maaslandziekenhuis, Sittard

08907

Hospital Duran I Reynals, Barcelona

L97LJ

Walton Hospital, Liverpool

Sponsors

Collaborators (1)

BioMS Technology Corp.
All Listed Sponsors
collaborator

BioMS Technology Corp.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY